SHAREHOLDER ALERT: Weiss Law is investigating Oyster Point Pharma, Inc.

NEW YORK, November 7, 2022 /PRNewswire/ —

Weiss’ law investigation of possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma, Inc. (“Oyster Point” or the “Company”) OYSTas part of the proposed acquisition of the Company by Viatris Inc. TRV by public takeover bid. Under the terms of the merger agreement, shareholders of the Company will receive $11.00 in cash for each common share of Oyster Point held, plus a contingent value right (“CVR”) representing the right to receive a potential cash payment of up to $2.00 per share.

If you own oyster tip actions and wish to discuss this survey or have questions about this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
Weiss’ law
305 Broadway, 7e Floor
New YorkNY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) Oyster Point’s board of directors acted in the best interests of the company’s shareholders in agreeing to the proposed transaction, (ii) the $11.00 the merger consideration per share adequately compensates Oyster Point shareholders, and (iii) all information regarding the sale process and valuation of the transaction will be fully and fairly disclosed. In particular, the merger consideration is less than the $21 median price target set by analysts, and at least one analyst has set a price target for the Company of $65 per share, $54.00 above the merger price per share.

Weiss Law has litigated hundreds of shareholder class and derivative actions for breach of corporate and fiduciary duties. We’ve recovered more than $1 billion for defrauded customers and won significant corporate governance relief in many of those cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumer rights (including false advertising, defective products or other deceptive marketing practices), or anti-trust violations, please email us at [email protected]

Show original content to download multimedia:

SOURCE Weiss’ Law

Comments are closed.